Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PANCREAS Clear all
Completed Not applicable Interventional Results available

Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients

NCT01784419
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ivacaftor, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cancer
Interventions
NIS793, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Not applicable Interventional Results available

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

NCT03369067
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

NCT02723331
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Industry
Eligibility
18 Years to 101 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT06921928
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
AZD4360
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Santa Monica, California • Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting Phase 2 Interventional

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

NCT07171112
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Recurrent Acute Pancreatitis, Smoking (Tobacco) Addiction
Interventions
Standard Varenicline Dosing (1 mg BID), Bupropion 150 mg twice daily, Increased Varenicline Dosing (1mg TID)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

NCT04659603
View directory record Official record
Conditions
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Interventions
tusamitamab ravtansine, Gemcitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Orlando, Florida • Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

NCT01509339
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Vancomycin
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577
View directory record Official record
Conditions
Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions
177Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jun 25, 2026, 11:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Not applicable Interventional

Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis

NCT00651053
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
EUS
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

NCT02921737
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TAS-102
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

NCT02018627
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Xeris glucagon, Lilly glucagon
Drug
Lead sponsor
Steven J. Russell, MD, PhD
Other
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jun 25, 2026, 11:07 AM EDT
Not listed No phase listed Observational

NCI SBIR Contract for Patient Navigation Tool Prototype Development

NCT04892927
View directory record Official record
Conditions
Pancreas Cancer, Hepatobiliary Cancer, Patient Engagement
Interventions
Not listed
Lead sponsor
GMG Arcdata LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Not applicable Interventional

A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

NCT01940237
View directory record Official record
Conditions
Depression, Pancreatic Cancer, Lung Cancer, Colon Cancer, Prostate Cancer
Interventions
Psychotherapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Not applicable Interventional

Effects of Innovative Aerobic Exercise Training in Cystic Fibrosis

NCT04543929
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
exercise
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

NCT02109445
View directory record Official record
Conditions
Metastatic Cancer Pancreas
Interventions
PF-03084014, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Aurora, Colorado • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting No phase listed Observational

Pancreatic Cancer Genetics

NCT01102569
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841
View directory record Official record
Conditions
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
Interventions
pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

NCT00068575
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Recombinant Interferon Alfa, Cisplatin, Fluorouracil, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting No phase listed Observational

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

NCT03250078
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
MRI/MRCP
Diagnostic Test
Lead sponsor
Nuvance Health
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

NCT02936323
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
Interventions
PEN-221
Drug
Lead sponsor
Tarveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

NCT00004003
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cisplatin, fluorouracil, gemcitabine hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

NCT01351103
View directory record Official record
Conditions
Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Cancer, Cervical Squamous Cell Cancer, Esophageal Squamous Cell Cancer, Lung Squamous Cell Cancer
Interventions
LGK974, PDR001
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jun 25, 2026, 11:07 AM EDT